Results, reports and publications
Latest results
Clariant delivers strong local currency sales growth in volatile trading conditions, confirms FY guidance
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
- Q3 2026 sales increased by 5.6 % in local currencies1 to CHF 968.8 million, with positive pricing and volumes in Care Chemicals and Adsorbents & Additives, while Catalysts’ volumes remain impacted by Middle East conflict
- Q3 2026 EBITDA margin before exceptional items decreased by 230 basis points to 15.6 % as continued improvement in Adsorbents & Additives was more than offset by two effects of broadly similar magnitude. First, Corporate costs had a positive phasing effect from prior year that normalized in the current year. Second, Care Chemicals and Catalysts saw a less favorable mix and volatile raw materials that affected costs and valuation of inventory
- 9M 2026 sales increased by 1 % in local currencies to CHF 2 828.1 million, driven by positive pricing with resilient volumes
- 9M 2026 EBITDA margin before exceptional items of 17.1 % versus 18.0 % in the prior year as margin improvement in Care Chemicals and Adsorbents & Additives was more than offset by the Middle East impact on Catalysts
- Free cash flow conversion improved by 9 percentage points to 48 % (LTM), achieved through improved operating cash flow, disciplined capex, and effective net working capital management
- Contributions from performance improvement programs delivered CHF 79 million run-rate cost savings
year to date (Q3 2026: CHF 10 million), on track to deliver full CHF 90 million in 2026- Guidance for 2026 remains unchanged with strong order book into end of the year
“In the third quarter of 2026, Clariant delivered strong local currency sales growth of 5.6 %, demonstrating the effectiveness of our price management and the resilience of our portfolio in a volatile operating environment. Care Chemicals and Adsorbents & Additives recorded pricing-led growth, while Catalysts’ volumes remained impacted by the Middle East conflict. Our Group EBITDA margin before exceptional items of 15.6 % reflects an improvement in Adsorbents & Additives, which was more than offset by two effects of broadly similar magnitude: a one-off year-onyear impact from the phasing of provisions in Corporate costs, and the combined impact of a less favorable mix and of volatile raw materials on cost and inventory valuation in Care Chemicals and Catalysts. Effective working capital management and disciplined capital expenditure improved free cash flow conversion by 9 percentage points to 48 % for the last twelve months, up from 39 % in the prior year,,” said Conrad Keijzer, Chief Executive Officer of Clariant.
“Our full year 2026 guidance remains unchanged, supported by a strong order book, particularly in Catalysts, for the fourth quarter and continued momentum in our performance improvement programs, which remain on track to deliver CHF 90 million in run-rate savings for 2026 and the full CHF 100 million by 2027. While inflationary pressures in raw materials, energy and logistics remain a challenge, our global production network and proven pricing capabilities position us well to protect margins as we close out the year,” Conrad Keijzer added.
1 All references to local currency growth, pricing, volumes, and scope exclude the impact from hyperinflation countries Argentina and Türkiye. All references to currency include a net impact from hyperinflation countries Argentina and Türkiye.
Read more
Results center
Please use the results center to find Clariant’s financial results and associated documents as published in the last five years
Q1 Q2 Q3 Q4 Date 29 April 2025 31 July 2025 30 October 2025 26 February 2026 Quiet period as of 10 April as of 9 July as of 8 October as of 19 January 2026 Media release EN EN EN EN Analyst presentation EN EN EN EN Webcast Audio recording MP3 MP3 MP3 MP3 Transcript EN EN EN EN Financial Review / HY report EN - XLS EN - XLS Annual report EN
Q1 Q2 Q3 Q4 Date 30 April 2024 30 July 2024 29 October 2024 28 February 2025 Quiet period as of 11 April as of 10 July as of 9 October as of 10 January 2025 Media release EN EN EN EN Analyst presentation EN EN EN EN Webcast Audio recording MP3 MP3 MP3 MP3 Transcript EN EN EN EN Financial Review / HY report EN - XLS EN - XLS Annual report EN
Q1 Q2 Q3 Q4 Date 5 May 2023 28 July 2023 30 October 2023 29 February 2024 Quiet period as of 17 April as of 10 July as of 10 October as of 15 January Media release EN — DE EN — DE EN — DE EN — DE Analyst presentation EN EN EN EN Webcast Audio recording MP3 MP3 MP3 MP3 Transcript EN EN EN EN Financial Review / HY report EN EN — XLS Annual report EN
Q1 Q2 Q3 Q4 Date 15 June 2022 28 July 2022 27 October 2022 2 March 2023 Quiet period as of 11 July as of 10 October as of 17 February Media release EN — DE EN — DE EN — DE EN — DE Analyst presentation EN EN EN EN Webcast Audio recording MP3 MP3 MP3 MP3 Transcript
EN Financial Review / HY report EN EN Annual report EN
Conferences and roadshows
Clariant's management and Investor Relations team regularly participates in conferences and roadshows. Below you can find an overview of the presentations provided at such events in the last two years.
For an overview of upcoming events, please refer to the Financial calendar.